Preclinical investigations revealed the antineoplastic potential of Tucatinib within breast cancer models characterized by HER2 overexpression, with augmented antineoplastic efficacy observed when administered in conjunction with Trastuzumab or Capecitabine [104]. The gene discussed is ERBB2; the disease is breast cancer.